Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

Rakin Chowdhury, Kate Manos, Melinda Burgess, Geoffrey Chong, Sze-Ting Lee, Zachary Hawula, Nella Tuczko, Charmaine Smith, Tineke Fancourt, Leonid Churilov, Andrew Scott, Allison Barraclough, Joel Wight, Joe McKendrick, Wendi Lin, Fiona Swain, Eliza A. Hawkes, Colm Keane

Blood (2024) 144 (Supplement 1): 6213.

https://doi.org/10.1182/blood-2024-201230

Published: 2024

Journal Articles

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rachel Koldej, Allison Barraclough, Sze Ting Lee, Huw Morgan, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes

Blood (2024) 144 (Supplement 1): 4376.

https://doi.org/10.1182/blood-2024-199854

Published: 2024

Journal Articles

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

Geoff Chong, Jodie B Palmer, Allison A Barraclough, Leonid Churilov, Colm Keane, Sze Ting Lee, Denise Lee, Sumita Ratnasingam, Charmaine Smith, Eliza A Hawkes

Blood (2023) 142 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2023-173110

Published: 2023

Journal Articles

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Blood (2023) 142 (Supplement 1): 735.

https://doi.org/10.1182/blood-2023-178403

Published: 2023

Journal Articles

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, MBBS, Masa Lasica, MD, Andrew Grigg, MBBS, MD FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Jonathan Wong, MBBS, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Gareth P. Gregory, Shane A Gangatharan, MBBS, FRACP, FRCPA, Tara Cochrane, MBBS,FRCPA,FRACP, Kristen Piper, Leonid Churilov, Eliza A Hawkes, FRACP,MDMBBS

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-138642

Published: 2020

Journal Articles

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Eliza A Hawkes, FRACP,MDMBBS, Geoffrey Chong, MD, Charmaine Smith, Sze-Ting Lee, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, MBBS, Niles Elizabeth Nelson, BSc, MBBS, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, MBBS, MD FRACP, FRCPA, Colm Keane, MD, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Kate Manos, MBBS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136024

Published: 2020

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?

Melissa Garwood, Eliza A Hawkes, Leonid Churilov, Andrew Grigg, MBBS, MD FRACP, FRCPA, Geoff Chong, MD

Blood (2016) 128 (22): 4217.

https://doi.org/10.1182/blood.V128.22.4217.4217

Published: 2016

Journal Articles

Limited Utility of Routine Chest X-Ray (CXR) in Initial Evaluation of Febrile Neutropenia in Patients with Haematological Diseases Undergoing Chemotherapy

Ortis Estacio, Zoe Loh, Andrew Grigg, MBBS, MD FRACP, FRCPA, Amy Baker, Leonid Churilov, Geoff Chong, MD, Eliza A Hawkes

Blood (2016) 128 (22): 3549.

https://doi.org/10.1182/blood.V128.22.3549.3549

Published: 2016

NARROW

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?

Limited Utility of Routine Chest X-Ray (CXR) in Initial Evaluation of Febrile Neutropenia in Patients with Haematological Diseases Undergoing Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only